{"id":"https://genegraph.clinicalgenome.org/r/d3c23ba7-1177-4a6f-bc8d-cc63f391e078v1.0","type":"EvidenceStrengthAssertion","dc:description":"*DPM3* was first reported in relation to autosomal recessive Congenital Disorders of Glycosylation by Lefeber DJ et al., 2009 (PMID: 19576565). At least 5 unique variants, all missense, have been reported in humans. Evidence supporting this gene-disease relationship includes both case-level data and experimental findings. Variants in this gene have been reported in at least 10 probands from publications (PMIDs: 19576565, 28803818, 30931530, 31266720, 31469168, 35932216). Patients exhibit a range of symptoms, including muscle weakness, creatine kinase elevation, cardiomyopathy, developmental delay, microcephaly, and neurological symptoms. Common neurological phenotypes associated with *DPM3* mutations include seizures, motor signs such as Babinski and Gowers signs, and other abnormalities like cerebral arteriovenous malformation, abnormal brain morphology, ataxia, dysarthria, and focal-onset seizures with associated motor and sensory deficits. No supporting segregation information is available, and the disease mechanism appears to be biallelic loss of function. Heterozygous carriers are reportedly unaffected. This gene-disease relationship is supported by the biochemical function of *DPM3*, which encodes the stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex, tethering catalytic subunit *DPM1* to the endoplasmic reticulum (PMID: 10835346). Altered expression of DPM3 in patients shows that DPM synthase activity in all patient cells was reduced by more than 70%. Immunoblotting in those same cells revealed a significant reduction in IIH6 labeling, indicating glycosylation problems (PMID: 30931530). In summary, there is strong evidence supporting this gene-disease relationship. Although additional genetic and experimental evidence is needed to establish a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. A classification of **MODERATE** was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on 12/6/23 (SOP Version 10).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/d3c23ba7-1177-4a6f-bc8d-cc63f391e078","GCISnapshot":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2023-12-06T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2023-12-21T14:17:56.599Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5c564dfc-1827-4f52-ad6a-cc4e475b93b5","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76ba4c10-aa00-4cfb-8255-c7464f057666","type":"FunctionalAlteration","dc:description":"To explore O-glycosylation and N-glycosylation in skeletal muscle, they conducted immunoblotting of glycosylated α-dystroglycan (αDG) and β-dystroglycan (βDG) in skeletal muscle homogenates from all three patients with DPM3-CDG. The IIH6 labeling showed a significant reduction, indicating agreement with dystroglycanopathy.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30931530","rdfs:label":"Immunoblotting of Skeletal Muscle"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/436b7d51-b90a-4b4d-8f06-d36715e2ca21","type":"EvidenceLine","dc:description":"This pathway is well defined ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3fdc790e-4a57-4fce-9600-cfd1273460a7","type":"Finding","dc:description":"Patients with this mutations in this gene show phenotypes associated with muscular dystrophy and  similar to other types of CDG.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835346","rdfs:label":"Maeda et al. Biochemical evidence of DPM3","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a1d5aa9b-ebf1-4760-a5b2-d909e45df47f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7578979-c379-46d4-b568-fe903e7e7b48","type":"Finding","dc:description":"DMP synthase activity in all patient cells was reduced by more than 70%. The reduction was more severe in patients 1 (12.7%) and 2 (2.8%) that harbor the Leu85Ser mutation in the coiled-coil domain of DPM3.\n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30931530","rdfs:label":"DPM3 Expression in Patient cells","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08fbab3d-612b-46f4-ba8b-36e65b1f4233_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5919eba-8e81-4c9d-a1c5-7e8c3d56c404","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5919eba-8e81-4c9d-a1c5-7e8c3d56c404_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfecting CHO2.38 cells with full-length DPM3 successfully restored Dol-P-Man synthase activity, while transfection with plasmids DeltaC and the L74S/L85S double mutant showed no complementation. However, transfection with the L85S mutant resulted in slight Dol-P-Man production) from PMID: 19576565.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d5919eba-8e81-4c9d-a1c5-7e8c3d56c404_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30931530","allele":{"id":"https://genegraph.clinicalgenome.org/r/8eab2b80-3e2a-4d16-b725-ec4bf7312d3f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_153741.2(DPM3):c.254T>C (p.Leu85Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA253249"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/08fbab3d-612b-46f4-ba8b-36e65b1f4233","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30931530","rdfs:label":"Patient 1 ","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":9,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8eab2b80-3e2a-4d16-b725-ec4bf7312d3f"},"detectionMethod":"DPM3 was sequenced","firstTestingMethod":"PCR","phenotypeFreeText":"serum TSH: 7.95 μIU/mL\n\nelevated transaminases: serum SGOT: 146 U/L; SGPT: 150 U/L\n\ncreatine kinase levels: 2680 U/L\n\nA quadriceps muscle biopsy showed a myopathic pattern with a number of regenerating fibers and a significantly increased number of internal nuclei\"\n\ndecreased contractility of the left ventricle\n\nmild bilateral gastrocnemius pseudohypertrophy","phenotypes":["obo:HP_0003198","obo:HP_0003642","obo:HP_0030046","obo:HP_0000821","obo:HP_0001644"],"previousTestingDescription":"An alpha-glucosidase activity assay excluded Pompe disease, and further molecular studies excluded Limb Girdle Muscular Dystrophy 2A (CAPN3 gene) and dystrophinopathy (DMD gene). Further metabolic testing included serum transferrin isoelectric focusing (TIEF), which showed a type 1 pattern.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d5919eba-8e81-4c9d-a1c5-7e8c3d56c404_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/8eb237b1-6ec5-4135-811d-01c8766e3843_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51667a81-fa7f-47af-b782-34646aa835ad","type":"EvidenceLine","dc:description":"African/African American: 1/16058 (0.00006227)","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51667a81-fa7f-47af-b782-34646aa835ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_153741.2(DPM3):c.131A>G (p.Tyr44Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342664394"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/8eb237b1-6ec5-4135-811d-01c8766e3843","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","rdfs:label":"Patient 4","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":26,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0001638","obo:HP_0001263","obo:HP_0001249"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/51667a81-fa7f-47af-b782-34646aa835ad_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/c0d61f8f-9ac8-43ab-b476-78aeb112a878_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/325c949e-1107-4094-95e8-c135e5d5979b","type":"EvidenceLine","dc:description":" European (non-Finnish): 33/1180048 (0.00002796)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/325c949e-1107-4094-95e8-c135e5d5979b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31266720","allele":{"id":"https://genegraph.clinicalgenome.org/r/cc758fdc-ba9c-43bf-97da-848ed0164379","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_153741.2(DPM3):c.41T>C (p.Leu14Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1138443"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/c0d61f8f-9ac8-43ab-b476-78aeb112a878","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31266720","rdfs:label":"Patient 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":33,"allele":{"id":"https://genegraph.clinicalgenome.org/r/cc758fdc-ba9c-43bf-97da-848ed0164379"},"detectionMethod":"next generation sequencing of 18 alpha-dystroglycanopathies genes; (fig.3F), confirmed by Sanger sequencing (Fig. 3G)","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":" CK (4700 IU/L)\n\nElectrocardiogram found left anterior hemiblock and right bundle-branch block.","phenotypes":["obo:HP_0012377","obo:HP_0030234","obo:HP_0009053","obo:HP_0003691","obo:HP_0002408","obo:HP_0001279","obo:HP_0008994","obo:HP_0003642","obo:HP_0002140","obo:HP_0031319","obo:HP_0002540","obo:HP_0001269","obo:HP_0008981","obo:HP_0001644","obo:HP_0007359"],"previousTesting":true,"previousTestingDescription":"Manual muscle testing (MRC grades) found the following abnormalities: deltoids 4/5, biceps 4/5, psoas 3/5, quadriceps 4/5, hamstrings 4/5, left tibialis anterior 4/5, and right tibialis anterior 2/5.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/325c949e-1107-4094-95e8-c135e5d5979b_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/14fc46de-a63e-4ffb-9f0f-37a0c143a629_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/690ddbcf-f56a-4770-8d08-ff1537065e82","type":"EvidenceLine","dc:description":" European (non-Finnish): 33/1180048 (0.00002796)","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/690ddbcf-f56a-4770-8d08-ff1537065e82_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28803818","allele":{"id":"https://genegraph.clinicalgenome.org/r/cc758fdc-ba9c-43bf-97da-848ed0164379"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/14fc46de-a63e-4ffb-9f0f-37a0c143a629","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28803818","rdfs:label":"Patient (Van den Bergh et. al)","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":30,"allele":{"id":"https://genegraph.clinicalgenome.org/r/cc758fdc-ba9c-43bf-97da-848ed0164379"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"deltoid muscle biopsy only showed mild nonspecific myopathic changes\n\nserum creatine kinase (CK): 4310  (IU/L)","phenotypes":["obo:HP_0002359","obo:HP_0003391","obo:HP_0008994","obo:HP_0045054","obo:HP_0003560","obo:HP_0030046"],"previousTesting":true,"previousTestingDescription":"Manual muscle testing (MRC grades) showed the following abnormalities: gluteus maximus 0/5; iliopsoas and quadriceps 3/5; gluteus medius and adductors 2/5; hamstrings 4/5, tibialis anterior, tibialis posterior, peroneus longus, and triceps surae 3/5.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/690ddbcf-f56a-4770-8d08-ff1537065e82_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/dac2b3f3-a677-46b6-a023-87bcd95991a3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10c2f115-f0c4-4209-a782-509feb00eadc","type":"EvidenceLine","dc:description":"African/African American: 1/16058 (0.00006227)","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10c2f115-f0c4-4209-a782-509feb00eadc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/dac2b3f3-a677-46b6-a023-87bcd95991a3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","rdfs:label":"Patient 3","ageType":"AgeAtReport","ageUnit":"Months","ageValue":30,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001252","obo:HP_0002910","obo:HP_0001324","obo:HP_0001260","obo:HP_0001251","obo:HP_0030234","obo:HP_0001250","obo:HP_0001263","obo:HP_0000252"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/10c2f115-f0c4-4209-a782-509feb00eadc_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/76bcf111-b22b-4be4-8fe7-870c9744bf44_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6df016bc-97d0-4380-97f1-4d45cc92d2fa_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","rdfs:label":"Family 1","estimatedLodScore":0.73,"family":{"id":"https://genegraph.clinicalgenome.org/r/6df016bc-97d0-4380-97f1-4d45cc92d2fa","type":"Family","rdfs:label":"Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/2447c08d-ef20-4beb-a5e8-2bdddcbc18aa","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","rdfs:label":"Patient 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":" muscle atrophy, afebrile tonic seizures\n\ncreatine kinase (CK): 1500 U/L\n\nelectroencephalogram (EEG) showed scattered sharp waves; distal and proximal lower limbs showed myopathic changes without signs of acute denervation","phenotypes":["obo:HP_0002910","obo:HP_0001508","obo:HP_0001324","obo:HP_0002373","obo:HP_0030234","obo:HP_0002607","obo:HP_0000252","obo:HP_0001252","obo:HP_0001263","obo:HP_0000020"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/748cedea-263b-4355-9111-0132b7d00216_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":" muscle atrophy, afebrile tonic seizures\n\ncreatine kinase (CK): 1500 U/L\n\nelectroencephalogram (EEG) showed scattered sharp waves; distal and proximal lower limbs showed myopathic changes without signs of acute denervation","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000020","obo:HP_0002373","obo:HP_0030234","obo:HP_0001263","obo:HP_0002910","obo:HP_0000252","obo:HP_0002607","obo:HP_0001508","obo:HP_0001252","obo:HP_0001324"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/2447c08d-ef20-4beb-a5e8-2bdddcbc18aa"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ccc78392-35f0-429b-b47a-f60491738307_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25809bb7-7e6d-41d6-82e1-e6ab7734accd","type":"EvidenceLine","dc:description":"European (non-Finnish): 33/1180048 (0.00002796)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25809bb7-7e6d-41d6-82e1-e6ab7734accd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31266720","allele":{"id":"https://genegraph.clinicalgenome.org/r/cc758fdc-ba9c-43bf-97da-848ed0164379"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/ccc78392-35f0-429b-b47a-f60491738307","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31266720","rdfs:label":"Patient 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":22,"allele":{"id":"https://genegraph.clinicalgenome.org/r/cc758fdc-ba9c-43bf-97da-848ed0164379"},"detectionMethod":"next generation sequencing of 18 alpha-dystroglycanopathies genes","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"An echocardiographic examination revealed a dilated, hypokinetic left ventricle with a reduced left ventricular ejection fraction (46%)\n\nSerum creatine kinase (CK): 4054 IU/L\n\nelectromyography showed myopathic changes in the deltoid and quadriceps muscles","phenotypes":["obo:HP_0003691","obo:HP_0003391","obo:HP_0009053","obo:HP_0008981","obo:HP_0030234","obo:HP_0003642","obo:HP_0001712","obo:HP_0008994","obo:HP_0002875"],"previousTesting":true,"previousTestingDescription":"Western blotting confirmed αDG hypoglycosylation","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/25809bb7-7e6d-41d6-82e1-e6ab7734accd_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2447c08d-ef20-4beb-a5e8-2bdddcbc18aa_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/748cedea-263b-4355-9111-0132b7d00216","type":"EvidenceLine","dc:description":"African/African American: 1/16058\t(0.00006227)","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/748cedea-263b-4355-9111-0132b7d00216_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/2447c08d-ef20-4beb-a5e8-2bdddcbc18aa"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/f97073b8-dbdb-4c6d-9eee-51fecab27133_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7419f79-5cd0-4af3-bf15-10220597a61f","type":"EvidenceLine","dc:description":"East Asian: 1/18366 (0.00005445) (v2.1.1)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7419f79-5cd0-4af3-bf15-10220597a61f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31469168","allele":{"id":"https://genegraph.clinicalgenome.org/r/deee9f22-1c23-4cd2-9a3f-7bba802e7a18","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_153741.2(DPM3):c.124C>G (p.Pro42Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1138427"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/9b4b2f49-ca85-4aad-ba7d-d090017c15b2","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9b4b2f49-ca85-4aad-ba7d-d090017c15b2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfecting CHO2.38 cells with full-length DPM3 successfully restored Dol-P-Man synthase activity, while transfection with plasmids DeltaC and the L74S/L85S double mutant showed no complementation. However, transfection with the L85S mutant resulted in slight Dol-P-Man production) from PMID: 19576565","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/9b4b2f49-ca85-4aad-ba7d-d090017c15b2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31469168","allele":{"id":"https://genegraph.clinicalgenome.org/r/0881861e-e4b4-4856-a226-0a7af7911008","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_153741.2(DPM3):c.254T>A (p.Leu85Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342662454"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/f97073b8-dbdb-4c6d-9eee-51fecab27133","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31469168","rdfs:label":"Patient (Fu et. al)","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/deee9f22-1c23-4cd2-9a3f-7bba802e7a18"},{"id":"https://genegraph.clinicalgenome.org/r/0881861e-e4b4-4856-a226-0a7af7911008"}],"detectionMethod":"Next-generation sequencing focusing on neuromuscular disorders and epilepsy including 15 dystroglycanopathies-associated genes","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"CK levels ranged from 500 to 2000 U/L\n\nBrain magnetic resonance imaging revealed mild white matter abnormality around lateral ventricles","phenotypes":["obo:HP_0012443","obo:HP_0030234","obo:HP_0002121","obo:HP_0001250","obo:HP_0001263"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d7419f79-5cd0-4af3-bf15-10220597a61f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/9b4b2f49-ca85-4aad-ba7d-d090017c15b2_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/574081fb-1ae8-4b85-b18d-2a95cb788572_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e78643a-4eb5-46e1-b69a-32b9470e69d2","type":"EvidenceLine","dc:description":"European (non-Finnish): 1/349506 (0.000002861)","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e78643a-4eb5-46e1-b69a-32b9470e69d2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfecting CHO2.38 cells with full-length DPM3 successfully restored Dol-P-Man synthase activity, while transfection with plasmids DeltaC and the L74S/L85S double mutant showed no complementation. However, transfection with the L85S mutant resulted in slight Dol-P-Man production","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2e78643a-4eb5-46e1-b69a-32b9470e69d2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19576565","allele":{"id":"https://genegraph.clinicalgenome.org/r/8eab2b80-3e2a-4d16-b725-ec4bf7312d3f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/574081fb-1ae8-4b85-b18d-2a95cb788572","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19576565","rdfs:label":"Patient (Lefeber et. al)","ageType":"AgeAtReport","ageUnit":"Years","ageValue":27,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8eab2b80-3e2a-4d16-b725-ec4bf7312d3f"},"detectionMethod":"direct sequencings of the 3 genes of the Dol-P-Man synthase complex","firstTestingMethod":"PCR","phenotypeFreeText":"Elevated CK: 1500 to 3000 U/L\n\nMildly elevated transaminases (ASAT 80, ALAT 98, normal < 50 IU/L)","phenotypes":["obo:HP_0003487","obo:HP_0001644","obo:HP_0003198","obo:HP_0001324","obo:HP_0001315","obo:HP_0002515","obo:HP_0002910","obo:HP_0030234","obo:HP_0003701","obo:HP_0003642","obo:HP_0003560"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/2e78643a-4eb5-46e1-b69a-32b9470e69d2_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/75eceb3a-9065-478b-ae27-8c16a8d861a1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c7397680-fb05-4299-a3e6-1b3548924e0d","type":"EvidenceLine","dc:description":"African/African American: 1/16058 (0.00006227)","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c7397680-fb05-4299-a3e6-1b3548924e0d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/75eceb3a-9065-478b-ae27-8c16a8d861a1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35932216","rdfs:label":"Patient 5","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a5426801-06df-4aa9-a68f-f96883b42c30"},"detectionMethod":"Trio whole exome sequencing\n","phenotypeFreeText":"recurrent generalized seizures since infancy; The EEG showed changes suggestive of generalised epilepsy; myography revealed myopathic features\n\nSerum CK: 1507 U/L;  ammonia levels: 53 μmol/L\n","phenotypes":["obo:HP_0002540","obo:HP_0034295","obo:HP_0000252","obo:HP_0002280","obo:HP_0001263","obo:HP_0001252","obo:HP_0001324","obo:HP_0030234"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c7397680-fb05-4299-a3e6-1b3548924e0d_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.4}],"evidenceStrength":"Moderate","sequence":7299,"specifiedBy":"GeneValidityCriteria10","strengthScore":6.4,"subject":{"id":"https://genegraph.clinicalgenome.org/r/XfIki1oqIgI","type":"GeneValidityProposition","disease":"obo:MONDO_0013049","gene":"hgnc:3007","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_76bcf111-b22b-4be4-8fe7-870c9744bf44-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}